Literature DB >> 27919490

Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.

Erin E Longbrake1, Samantha Lancia2, Nhial Tutlam2, Kathryn Trinkaus3, Robert T Naismith2.   

Abstract

BACKGROUND: Visual dysfunction in MS can be quantified using a variety of tests. Many vision tests have not been formally evaluated among MS patients with existing visual dysfunction.
OBJECTIVE: Evaluate several versions of visual acuity and contrast sensitivity tests, measures of central and peripheral vision, retina structure, electrophysiologic function, and quality of life among MS patients with moderate/severe visual dysfunction.
METHODS: Cross-sectional study of 46 patients with stable, incompletely recovered optic neuritis. Testing included Snellen eye charts, several Sloan low contrast charts, Pelli Robson (PR) contrast sensitivity charts, optical coherence tomography, visual fields, Farnsworth Munsell 100-hue test, visual evoked potentials (VEP), and visual function quality of life (VFQ-25) testing.
RESULTS: 98% of eyes could read two lines of the PR chart, while only 43% read the 2.5% contrast chart. Low contrast tests correlated strongly with each other and with retinal nerve fiber layer (RNFL) thickness, visual fields, and color vision but not with VEPs. For patients with RNFL <75µm, VFQ-25 scores dropped by approximately 2 points for every 1µm decrease in RNFL.
CONCLUSION: Among MS patients with visual impairment due to optic neuritis, PR contrast sensitivity could be utilized as a single chart. Visual quality of life was associated with RNFL thinning below 75µm. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Multiple sclerosis; Visual acuity

Mesh:

Year:  2016        PMID: 27919490      PMCID: PMC5392253          DOI: 10.1016/j.msard.2016.10.009

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  36 in total

Review 1.  The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system.

Authors:  W I McDonald; D Barnes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

2.  Development of the 25-item National Eye Institute Visual Function Questionnaire.

Authors:  C M Mangione; P P Lee; P R Gutierrez; K Spritzer; S Berry; R D Hays
Journal:  Arch Ophthalmol       Date:  2001-07

3.  New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis.

Authors:  L J Balcer; M L Baier; V S Pelak; R J Fox; S Shuwairi; S L Galetta; G R Cutter; M G Maguire
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

4.  Colour vision impairment is associated with disease severity in multiple sclerosis.

Authors:  Elena H Martínez-Lapiscina; Santiago Ortiz-Pérez; Elena Fraga-Pumar; Eloy Martínez-Heras; Iñigo Gabilondo; Sara Llufriu; Santiago Bullich; Marc Figueras; Albert Saiz; Bernardo Sánchez-Dalmau; Pablo Villoslada
Journal:  Mult Scler       Date:  2014-01-07       Impact factor: 6.312

5.  Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis.

Authors:  V Pueyo; J Martin; J Fernandez; C Almarcegui; J Ara; C Egea; L Pablo; F Honrubia
Journal:  Mult Scler       Date:  2008-04-18       Impact factor: 6.312

6.  Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.

Authors:  L J Balcer; M L Baier; J A Cohen; M F Kooijmans; A W Sandrock; M L Nano-Schiavi; D C Pfohl; M Mills; J Bowen; C Ford; F R Heidenreich; D A Jacobs; C E Markowitz; W H Stuart; G-S Ying; S L Galetta; M G Maguire; G R Cutter
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

7.  In vivo evaluation of retinal neurodegeneration in patients with multiple sclerosis.

Authors:  Erika Tátrai; Magdolna Simó; Anna Iljicsov; János Németh; Delia Cabrera Debuc; Gábor Márk Somfai
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

8.  Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population?

Authors:  Christopher G Owen; Alicja R Rudnicka; Liam Smeeth; Jennifer R Evans; Richard P L Wormald; Astrid E Fletcher
Journal:  BMC Ophthalmol       Date:  2006-06-09       Impact factor: 2.209

Review 9.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

10.  Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.

Authors:  Jennifer Graves; Steven L Galetta; Jeffrey Palmer; David H Margolin; Marco Rizzo; John Bilbruck; Laura J Balcer
Journal:  Mult Scler       Date:  2013-03-04       Impact factor: 6.312

View more
  6 in total

1.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

2.  Predictors of vision impairment in Multiple Sclerosis.

Authors:  Bernardo Sanchez-Dalmau; Elena H Martinez-Lapiscina; Irene Pulido-Valdeolivas; Irati Zubizarreta; Sara Llufriu; Yolanda Blanco; Nuria Sola-Valls; Maria Sepulveda; Ana Guerrero; Salut Alba; Magi Andorra; Anna Camos; Laura Sanchez-Vela; Veronica Alfonso; Albert Saiz; Pablo Villoslada
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

Review 3.  The electrophysiological assessment of visual function in Multiple Sclerosis.

Authors:  Joshua L Barton; Justin Y Garber; Alexander Klistorner; Michael H Barnett
Journal:  Clin Neurophysiol Pract       Date:  2019-05-08

4.  Low Contrast Visual Acuity Might Help to Detect Previous Optic Neuritis.

Authors:  Soo-Hyun Park; Choul Yong Park; Young Joo Shin; Kyoung Sook Jeong; Nam-Hee Kim
Journal:  Front Neurol       Date:  2020-12-22       Impact factor: 4.003

5.  Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.

Authors:  Lisanne J Balk; Danko Coric; Jenny A Nij Bijvank; Joep Killestein; Bernard Mj Uitdehaag; Axel Petzold
Journal:  Mult Scler       Date:  2017-05-17       Impact factor: 6.312

Review 6.  Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence.

Authors:  Axel Petzold; Tasanee Braithwaite; Bob W van Oosten; Lisanne Balk; Elena H Martinez-Lapiscina; Russell Wheeler; Nils Wiegerinck; Christiaan Waters; Gordon T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-11-18       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.